Trial reportStem cells translational medicine2017
Effects of Transendocardial CD34
Trial report in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction.European journal of heart failure · 2022Trial
- The Landscape of Advanced Therapy Medicinal Products in Slovenian Transfusion Medicine: A Review of Past and Future Outlook.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Current concepts and challenges in pediatric diastolic dysfunction and heart failure with preserved ejection fraction.Pediatric research · 2026Review
- Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy.ESC heart failure · 2025Observational
- The Application of Mesenchymal Stem Cells in Different Cardiovascular Disorders: Ways of Administration, and the Effectors.Stem cell reviews and reports · 2024Review
- Relation between cardiac magnetic resonance-assessed interstitial fibrosis and diastolic dysfunction in heart failure due to dilated cardiomyopathy.International journal of cardiology. Heart & vasculature · 2024Article
- In Search of the Holy Grail: Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved Ejection Fraction.International journal of molecular sciences · 2023Review
- Cell Therapy in Heart Failure with Preserved Ejection Fraction.Cardiac failure review · 2022Review
- Transplantation of CD34+ cells for myocardial ischemia.World journal of transplantation · 2021Review
- Review
- Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy.International journal of molecular sciences · 2020Review
- Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to evaluate the physiological background and the effects of CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.